The letter did not raise any concerns regarding clinical safety or efficacy data. The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals ...

A warning letter ... FDA inspection last year of Dexcom’s facilities in San Diego and Mesa, Arizona. Marcus wrote that after the FDA requested additional information and a separate 510(k ...